ArticleEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V2015
Development of a highly thermostable, adjuvanted human papillomavirus vaccine.
Article in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Article
- Superior immune responses from thermostable, single-administration rabies vaccines prepared using atomic layer deposition.Journal of pharmaceutical sciences · 2025Article
- Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded.Infectious agents and cancer · 2025Review
- Can prophylactic HPV vaccination reduce the recurrence of cervical lesions after surgery? Review and prospect.Infectious agents and cancer · 2023Review
- A Single Dose, Thermostable, Trivalent Human Papillomavirus Vaccine Formulated Using Atomic Layer Deposition.Journal of pharmaceutical sciences · 2023Article
- Updates on HPV Vaccination.Diagnostics (Basel, Switzerland) · 2023Review
- New Perspectives in Therapeutic Vaccines for HPV: A Critical Review.Medicina (Kaunas, Lithuania) · 2022Review
- Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications.Nano convergence · 2022Review
- Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance.Frontiers in cell and developmental biology · 2022Review
- Article
- Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.Human vaccines & immunotherapeutics · 2021Article
- Development of thermostable vaccine adjuvants.Expert review of vaccines · 2021Review
- RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates.Journal of clinical medicine · 2021Review
- Single-administration, thermostable human papillomavirus vaccines prepared with atomic layer deposition technology.NPJ vaccines · 2020Article
- Dose finding for new vaccines: The role for immunostimulation/immunodynamic modelling.Journal of theoretical biology · 2019Article
- Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2019Article
- Opportunities and challenges for human papillomavirus vaccination in cancer.Nature reviews. Cancer · 2018Review
- Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.Frontiers in immunology · 2018Review
- Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making.NPJ vaccines · 2018Article
- Economic impact of thermostable vaccines.Vaccine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
A major impediment to economical, worldwide vaccine distribution is the requirement for a "cold chain" to preserve antigenicity. We addressed this problem using a model human papillomavirus (HPV) vaccine stabilized by immobilizing HPV16 L1 capsomeres, i.e., pentameric subunits of the virus capsid, within organic glasses formed by lyophilization. Lyophilized glass and liquid vaccine formulations were incubated at 50°C for 12weeks, and then analyzed for retention of capsomere conformational integrity and the ability to elicit neutralizing antibody responses after immunization of BALB/c mice. Capsomeres in glassy-state vaccines retained tertiary and quaternary structure, and critical conformational epitopes. Moreover, glassy formulations adjuvanted with aluminum hydroxide or aluminum hydroxide and glycopyranoside lipid A were not only as immunogenic as the commercially available HPV vaccine Cervarix®, but also retained complete neutralizing immunogenicity after high-temperature storage. The thermal stability of such adjuvanted vaccine powder preparations may thus eliminate the need for the cold chain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.